Dabigatran
- OralDabigatranPradaxa
Mechanism of Action
- Reversibly inhibits factor IIa (thrombin), resulting in reduced fibrin clot formation.
Pharmacology
- Idarucizumab (praxbind) may be used to reverse dabigatran in life-threatening situations only.
Clinical Use
- Indications
- Prevention of venous thromboembolism post hip / knee surgery
- Treatment of venous thromboembolism (DVT / PE)
- Non-valvular atrial fibrillation (prevention of stroke)
- Contraindications
- Active bleeding or risk of major bleeding
- Use of other anticoagulants
- Mechanical heart valve
- Severe renal impairment (eGFR
- Adverse Effects
- Haemorrhage
- Oesophageal ulceration
Monitoring
- A dilute thrombin time assay may be used to monitor dabigatran.